VectivBio Announces Pricing of $125 Million Underwritten Offering of Ordinary Shares
October 13, 2022 07:20 ET
|
VectivBio AG
BASEL, Switzerland, Oct. 13, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for...
VectivBio Reports Positive Interim Clinical Data from STARS Nutrition, a Phase 2 Study Investigating Apraglutide in Short Bowel Syndrome with Intestinal Failure Patients (SBS-IF) with Colon-In-Continuity (CIC)
October 13, 2022 07:00 ET
|
VectivBio AG
• Treatment with apraglutide resulted in an average 50% reduction in Parenteral Support (PS) volume at six months • 80% of patients were clinical responders (defined as a reduction in volume of...
VectivBio Announces Date of Extraordinary General Meeting of Shareholders
October 12, 2022 10:00 ET
|
VectivBio AG
BASEL, Switzerland, Oct. 12, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for...
VectivBio Announces Closing of $54 Million Aggregate Financing
June 29, 2022 07:15 ET
|
VectivBio AG
BASEL, Switzerland, June 29, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for...
VectivBio Announces Pricing of $30 Million Public Offering of Ordinary Shares
June 14, 2022 21:03 ET
|
VectivBio AG
BASEL, Switzerland, June 14, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for...
VectivBio Announces Launch of Public Offering of Ordinary Shares
June 14, 2022 16:18 ET
|
VectivBio AG
BASEL, Switzerland, June 14, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for...
VectivBio Publishes Invitation to the Annual General Meeting
June 09, 2022 16:16 ET
|
VectivBio AG
BASEL, Switzerland, June 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for...
VectivBio Announces First Two Patients Dosed in Phase 2 STARGAZE Study of Apraglutide for the Treatment of Acute Graft-versus-Host Disease
June 02, 2022 08:15 ET
|
VectivBio AG
– Interim proof-of-concept data anticipated from STARGAZE in H1 2023 – First-in-class regenerative, non-immunosuppressive approach to treating acute Graft-versus-Host Disease – Second clinical...
VectivBio to Participate at the Bank of America 2022 Healthcare Conference
May 09, 2022 07:30 ET
|
VectivBio AG
BASEL, Switzerland, May 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for...
VectivBio Appoints Patrick Malloy as Senior Vice President, Investor Relations & Strategic Communications
April 21, 2022 07:15 ET
|
VectivBio AG
BASEL, Switzerland, April 21, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for...